BioSpace

Novo, Lilly battle for oral GLP-1 dominance with data tit for tat

Novo CEO Mike Maziar Doustdar insists that his company is ahead of fierce rival Eli Lilly as oral Wegovy rises to 8 million total prescriptions since its January launch.

By BioSpace

1 min read
Novo, Lilly battle for oral GLP-1 dominance with data tit for tat
AI-generated illustration

Got news to share with the events industry?

Submit a press release or story tip and reach thousands of event professionals.

Get in touch→

More in Health Tech

Related Insights